Effects of the Intermolecular Toxin-Monoclonal Antibody Linkage on the In Vivo Stability, Immunogenicity and Anti-Leukemic Activity of B43 (Anti-CD19) Pokeweed Antiviral Protein Immunotoxin

References

• Kersey J. H., Weisdorf D., Nesbit M. E., LeBien T. W., Woods W. G., McGlave P. B., Kim T., Vallera D. A., Goldman A. I., Bostrom B., Hurd D., Ramsay N. K. C. Comparison of autologous and allogenic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. New England Journal of Medicine 1987; 317: 461
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Kersey J. H., Haake R., Weisdorf D., Ramsay N. K. C. Autologous bone marrow transplantation in high risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1, BA-2, BA-3) plus complement and 4-hydroperoxycyclophos-phamide for ex vivo marrow purging. Blood 1992; 79: 1094
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Kersey J. H., Vallera D. A., Ledbetter J. A., Weisdorf D., Myers D. E., Haake R., Ramsay N. K. C. Autologous bone marrow transplantation in high risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging. Blood 1990; 76: 1723
   PubMed Web of Science ®Google Scholar
• Doney K., Buckner C. D., Kopecky K. J., Sanders J. E., Appelbaum F. R., Clift R., Sullivan K., Witherspoon R., Storb R., Thomas E. D. Marrow transplantation for patients with acute lymphoblastic leukemia in first marrow remission. Bone Marrow Transplantation 1987; 2: 355
   PubMed Web of Science ®Google Scholar
• Herzig R. H., Barrett A. J., Gluckman E., Jacobsen S. J., Masaoka T., Ramsay N. K. C., Ringden O., Zwaan F. E., Bortin M. M., Blume K. G., Horowitz M. M., Marmont A., Prentice H. G., Rimm A. A., Soeck B., Gale R. P. Bone-marrow transplantation in high-risk acute lymphoblastic leukaemia in first and second remission. Lancet 1987; 1: 786
   PubMed Web of Science ®Google Scholar
• Ramakrishnan S., Houston L. L. Inhibition of human acute lymphoblastic leukemic cells by immunotoxins: Potentiation by chloroquine. Science 1984; 223: 58
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Ramakrishnan S., Houston L. L. Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow. J. of Immunol. 1985; 134: 2010
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Gajl-Peczalska K. J., Kersey J. H., Houston L. L., Vallera D. A. Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia. J. of Exp. Med. 1986; 163: 347
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Gajl-Peczalska K., Myers D. E., Jaszcz W., Haissig S., Ledbetter J. A. Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood 1990; 76: 2449
   PubMed Web of Science ®Google Scholar
• Ghetie M. -A., May R. D., Till M., Uhr J. W., Ghetie V., Knowles P. P., Relf M., Brown A., Wallace P. M., Janossy G., Amlbt P., Vitetta E. S., Thorpe P. E. Evaluation of ricin A chain containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B cells as potential reagents for in vivo therapy. Cancer Res. 1988; 48: 2610
   PubMed Web of Science ®Google Scholar
• Grossbard M. L., Freedman A. S., Ritz J., Coral F., Goldmacher V. S., Eliseo L., Spector N., Dear K., Lambert J. M., Blaettler W. A., Taylor J. A., Nadler L. M. Serothearpy of B-cell neoplasms with antLB4-blocked ricin: A phase I trial of daily bolus infusion. Blood 1992; 79: 576
   PubMed Web of Science ®Google Scholar
• Vitetta E. S., Stone M., Amlot P., Fay J., May R., Till M., Newman J., Clark P., Collins R., Cunningham D., Ghetie V., Uhr J. W., Thorpe P. E. Phase I Immunotoxin Trial in Patients with B-cell Lymphoma. Cancer Research 1991; 51: 4052
   PubMed Web of Science ®Google Scholar
• Endo Y., Mitsiu K., Motizuki M., Tsurugi K. The mechanism of action of ricin and related toxin lectins on eukaryotic ribosomes. The site and characteristics of the modification in 28S ribosomal RNA caused by the toxins. J. Biol. Chem. 1987; 262: 5908
   PubMed Web of Science ®Google Scholar
• Uckun F. M. Anti-CD 19 immunotoxins for in vivo immunotherapy of B-lineage acute lymphoblastic leukemias. Antibody Immunoconjugates and Radiopharmaceutics 1988; 1: 247
   Google Scholar
• Uckun F. M., Jaszcz W., Ambrus J. L., Fauci A. S., Gajl-Peczalska K. J., Song C. W., Wick M. R., Myers D. E., Waddick K. G., Ledbetter J. A. Detailed studies on expression and function of CD19 surface determinant using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 1988; 7: 13
   Google Scholar
• Irvin J. D. Pokeweed Antiviral Protein. Pharmac. Ther. 1983; 21: 371
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Chelstrom L. C., Irvin J. D., Finnegan D., Gunther R., Young J., Kuebelbeck V., Myers D. E., Houston L. L. In vivo efficacy of B43(anti-CD19)-PAP immunotoxin against BCL-1 murine B-cell leukemia. Blood. 1992, in press.
   Google Scholar
• Uckun F. M., Manivel C., Arthur D., Chelstrom L., Finnegan D., Irvin J. D., Myers D. E., Chelstrom L. C. In vivo efficacy of B43(anti-CD19)-pokeweed antiviral protein (PAP) immunotoxin against human pre-B cell acute lymphoblastic leukemia (ALL) in mice with severe combined immunodeficiency (SCID). Blood. 1992, in press.
   Google Scholar
• Thorpe P. E., Wallace P. M., Knowles P. P., Relf M. G., Brown A. N. F., Watson G. J., Knyba R. E., Wawrzynczak E. J., Blakey D. C. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability. in vivo. Cancer Res 1987; 47: 5924
   PubMed Web of Science ®Google Scholar
• Myers D. E., Irvin J. D., Smith R. S., Kuebelbeck V. M., Uckun F. M. Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP. directed against the CD19 human B-lineage lymphoid differentiation antigen in highly purified form for human clinical trials. J. Immunol. Methods 1991; 136: 221
   PubMed Web of Science ®Google Scholar
• Zarling J. M., Moran P. A., Haffar O., Spina C. A., Sias J., Myers D. E., Kuebelbeck V., Ledbetter J. A., Richmand D. D., Uckun F. M. HIV replication inhibited by pokeweed antiviral protein targeted to CD4+ cells by antibodies. Nature 1990; 337: 92
   Web of Science ®Google Scholar
• Uckun F. M., Ledbetter J. A. Immunobiologic differences between normal and leukemic human B-cell precursors. Proc. Natl. Acad. Sci. U. S. A. 1988; 85: 8603
   PubMed Web of Science ®Google Scholar
• Uckun F. M. Regulation of human B-cell ontogeny (Review). Blood 1990; 76: 1908
   PubMed Web of Science ®Google Scholar
• Hertler A. A., Frankel A. E. Immunotoxins: A clinical review of their use in the treatment of malignancies. J. of Clin. Oncol. 1989; 7: 1932
   PubMed Web of Science ®Google Scholar
• Vitetta E. S., Uhr J. W., Thorpe P. E. Immunotoxin Therapy. Cancer: Principles and Practice of Oncology. 1993, Edition, in press.
   Google Scholar
• Fulton R. J., Tucker T. F., Vitetta E. S., Uhi J. W. Phannacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: Effect of antibody valency and deglycosylation of ricin A chain on clearance and tumor localization. Cancer Res. 1988; 48: 2618
   PubMed Web of Science ®Google Scholar
• Wawrzynczak E. J., Thorpe P. E. Methods for preparing immunotoxins: Effect of the linkage on activity and stability. [In]. Immunoconjugates, Antibody Conjugates in Radioimaging and Therapy of Cancer, Carl-Wilhelm Vogel, 1987; 28
   Google Scholar
• Ramakrishnan S., Houston L. L. Immunological and biological stability of immunotoxins in vivo as studied by the clearance of disulfide-linked pokeweed antiviral protein- antibody conjugates from blood. Cancer Res. 1985; 45: 2031
   PubMed Web of Science ®Google Scholar
• Wawrzynczak E. J., Cumber A. J., Henry R. V., May J., Newell D. R., Parnell G. D., Worrell N. R., Forrester J. A. Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin. Cancer Res 1990; 50: 7519
   PubMed Web of Science ®Google Scholar
• Blakey D. C., Skilleter D. N., Price R. J., Watson G. J., Hart L. I., Newell D. R., Thorpe P. E. Comparison of the pharmacokinetics and hepatotoxic effects of saporin and rich A chain immumotoxins on murine liver parenchymal cells. Cancer Res 1988; 48: 7072
   PubMed Web of Science ®Google Scholar
• Sivam G., Pearson J. W., Bohn W., Oldham R. K., Sadoff J. C., Morgan A. C., Jr. Immunotoxins to a human melanoma-associated antigen: comparison of gelonin with ricin and other A chain conjugates. Cancer Res 1987; 47: 3169
   PubMed Web of Science ®Google Scholar
• Reimann K. A., Turner S., Lambert J. M., Reed M. H., Schlossman S. F., Letvin N. L. In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. V. Evidence that humoral immune response to monoclonal antibodies and immunotoxin conjugates abrogates their cyiotoxic activity. Transplantation 1989; 48: 906
   PubMed Web of Science ®Google Scholar
• Press O. W., Appelbaum F., Ledbetter J. A., Martin P. J., Zarling J., Kidd P., Thomas E. D. Monoclonal antibody 1F5 (anti- CD20) serotherapy of human B cell lymphomas. Blood 1987; 69: 584
   PubMed Web of Science ®Google Scholar